Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo

Retinol-binding protein 4 (RBP4) transports retinol from the liver to extrahepatic tissues, and RBP4 lowering is reported to improve Insulin sensitivity in mice. We have identified A1120, a high affinity (K(i) = 8.3 nm) non-retinoid ligand for RBP4, which disrupts the interaction between RBP4 and its binding partner transthyretin. Analysis of the RBP4-A1120 co-crystal structure reveals that A1120 induces critical conformational changes at the RBP4-transthyretin interface. Administration of A1120 to mice lowers serum RBP4 and retinol levels but, unexpectedly, does not improve Insulin sensitivity. In addition, we show that Rpb4(-/-) mice display normal Insulin sensitivity and are not protected from high fat diet-induced Insulin Resistance. We conclude that lowering RBP4 levels does not improve Insulin sensitivity in mice. Therefore, RBP4 lowering may not be an effective strategy for treating diabetes.